Dana-Farber Cancer Institute

Dana-Farber Cancer Institute runs one of the more interesting threat models in American healthcare: an institution where clinical operations, pediatric and adult oncology, clinical trials, and research on HIV/AIDS and related diseases all sit on the same institutional substrate. It's a world-renowned cancer research and treatment center based in Boston, Massachusetts, and one of the leading cancer centers in the United States, with an academic affiliation to Harvard Medical School and partnerships including Beth Israel Deaconess Medical Center. Sensitive data here is not an abstraction - it's personalized treatment plans, trial protocols, and the patient and family support record that surrounds them.

The work spans comprehensive cancer care for adults and children, cutting-edge treatments delivered through clinical trials, integrative research programs that advance treatment options, and support services carried through the cancer journey. For security work, that means the domains in play are plural: clinical systems serving specialized treatment centers, research data pipelines, trial infrastructure, and the collaboration surface between physicians, researchers, and nurses. The care model is personalized; the underlying data handling has to be, too.

Culturally, the institute describes itself as mission-driven and united in conquering cancer, HIV/AIDS, and related diseases, with a collaborative team environment across clinical and research staff and a stated focus on compassionate, comprehensive care for patients of all backgrounds. Any security function operating here reports to that mission rather than around it - protecting an organization whose core assets are medical research, trial integrity, and the continuity of care for patients with very little margin for disruption.